Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J & J Warned Over Orthopedic Unit

By Drug Discovery Trends Editor | August 24, 2010

TRENTON, N.J. (AP) – A Johnson & Johnson business that makes joint replacements has been warned by the Food and Drug Administration that it’s illegally marketing two products.

The FDA notified Johnson & Johnson’s DePuy Orthopaedics Inc. that it is selling one product that was never approved for sale and is selling another product for uses that have not been specifically approved.

In a letter to the company, the FDA wrote that DePuy is marketing its Corail Hip System for two unapproved uses, and promoting those uses in an online brochure.

The agency also stated that it never approved the TruMatch Personalized Solution System. That’s a software system that uses high-tech scanning technology to create a detailed, 3-D view of a patient’s knee so a surgeon can properly position a knee implant.

The FDA has told DePuy, which is based in Warsaw, Ind., to stop selling the hip system for unapproved uses and to provide information that would be needed for the agency to approve the software system.

The FDA’s warning letter, addressed to DePuy President David Floyd, was posted on the agency’s website on Tuesday. The letter is dated Aug. 19.

It states that the Corail Hip System is approved for total hip replacement in patients with six specific types of damage to the hip. But a brochure on DePuy website claims the system can be used for treating two other conditions.

In early trading, Johnson & Johnson shares were down 78 cents at $58.08, while health-care stocks and the broader markets were all down sharply.

Mindy Tinsley, a spokeswoman for DePuy, said the company would provide comment later on Tuesday.

Johnson & Johnson is based in New Brunswick, N.J.

Date: August 24, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE